Canary Medical announced today that it completed the first-in-human limited feasibility trial of its cardiac auscultation monitoring device.
Vancouver, British Columbia–based Canary is developing the device as a first-in-class implantable sensor. It provides daily adjunctive objective cardiac parameter measurements. The company believes it could enable patients and clinicians to better manage congestive heart failure symptoms.
Canary Medical conducted its feasibility trial in Paraguay. The company says it marks the first successful human implantation of a cardiac auscultation sensor device. It designed the first-in-human trial to ascertain the sensitivity, specificity and final design specifications for the device’s microphone system.
The company says it successfully completed the trial comprised of two subjects. It demonstrated visible mitral regurgitation sound signals from the sensor compared to normal acoustic heart signals.
“Today Canary Medical announced the first step in expanding our sensor technology applications outside of orthopedics. The cardiac auscultation monitor is just one of the exciting new products that will drive the future growth of our company,” said Dr. Bill Hunter, founding member and CEO of Canary Medical. “Congratulations to our world-class research and development team and thank you to the individuals who were the first to receive this new technology. While these are early results, we believe that the future is bright for patients who will benefit from Canary’s expanded sensor portfolio in the years to come.”
More about Canary Medical
This marks the latest potential advance for Canary Medical, which already has a presence in the orthopedic implant space. The company hopes to make smart implants the next big thing.
Canary Medical develops the proprietary implantable Canturio TE tibial extension sensor technology. The sensor technology enables Zimmer Biomet’s Persona IQ smart knee implant. Persona IQ with the Canturio TE tibial extension sensor technology collects activity measures and gait parameters for at least 10 years. By pooling parameters across the Persona IQ patient population, recovery curves provide population data for activity levels and knee kinematics.
In August, 2021, Canary and Zimmer Biomet announced that the FDA granted de novo classification for Persona IQ. Earlier that year, Hunter described the highly anticipated technology to MassDevice and Medical Design & Outsourcing.
The company integrated a new analytic module with Zimmer Biomet’s technology in December 2022. The company intends to make its information useful for remote patient monitoring. Hunter spoke with MDO again about the company’s aims last fall as well.
Bill Hunter will be a speaker at DeviceTalks Boston May 1-2. Learn more about the event and register HERE.